5T4: a delicate target for sophisticated payload delivery – a pipeline review

STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of the free report Pipeline of 5T4-Targeted Immunotherapies to showcase its newest service of pipeline reviews. The free report reviews the pipeline of active anti-5T4 immunotherapeutics in R&D.

This competitive intelligence report about Pipeline of 5T4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting 5T4. Reports of this type of service will be prepared on demand within one working day upon order placement. Such reports list target-specific R&D programs by R&D phase in a tabular format and describe in brief the profile of the specific targeted immunotherapies by drug modality. The reports will be provided in pdf format and sent by e-mail to the customer.

Cell-surface protein trophoblast glycoprotein (TPBG) 5T4 is a highly expressed oncofetal tumor-associated antigen associated with adverse clinical outcomes in solid tumors, and is an attractive therapeutic target due to low expression on normal adult tissues, with most human expression being observed in utero. Analysis in fresh frozen healthy human tissue with the therapeutic mAb candidate of TUB-030 revealed limited cross reactivity. 5T4 is a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). 5T4 on tumor cell surface is rapidly internalized when bound to antibody and is thus an ideal target for the development of ADC drugs. However, the slow internalization rate and low surface density have limited 5T4 as a tumor associated antigen for ADC drug development so far, but leaving opportunities for more efficient ADC technologies.

The report “Pipeline of 5T4-Targeted Immunotherapies” can be downloaded for free at La Merie Publishing’s online store: https://lamerie.com/free-reports/pipeline-of-5t4-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing